Clinical trial
A Phase Ib/II Clinical Trial of JDB153 Combined With Penpulimab for the Treatment of Hepatocellular Carcinoma Refractory to Standard Therapy
NCT07075419 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib/II Clinical Trial of JDB153 Combined With Penpulimab for the Treatment of Hepatocellular Carcinoma Refractory to Standard Therapy
- Lead sponsor
- West China Hospital
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- August 1, 2025
- Completion date
- August 1, 2027
- Enrollment
- 10 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
refractory hepatocellular carcinoma